相似文献
1
Impact of CRISPR immunity on the emergence and virulence of bacterial pathogens.
Curr Opin Microbiol. 2014 Feb;17:82-90. doi: 10.1016/j.mib.2013.12.001. Epub 2013 Dec 29.
2
Suppressing the CRISPR/Cas adaptive immune system in bacterial infections.
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2043-2051. doi: 10.1007/s10096-017-3036-2. Epub 2017 Jun 11.
3
I can see CRISPR now, even when phage are gone: a view on alternative CRISPR-Cas functions from the prokaryotic envelope.
Curr Opin Infect Dis. 2015 Jun;28(3):267-74. doi: 10.1097/QCO.0000000000000154.
4
[CRISPR-Cas systems as weapons against pathogenic bacteria].
Biol Aujourdhui. 2017;211(4):265-270. doi: 10.1051/jbio/2018004. Epub 2018 Jun 29.
5
CRISPR-Cas systems: beyond adaptive immunity.
Nat Rev Microbiol. 2014 May;12(5):317-26. doi: 10.1038/nrmicro3241. Epub 2014 Apr 7.
6
Resistance is not futile: bacterial 'innate' and CRISPR-Cas 'adaptive' immune systems.
Microbiology (Reading). 2019 Aug;165(8):834-841. doi: 10.1099/mic.0.000802. Epub 2019 Apr 8.
7
Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of Klebsiella pneumoniae.
BMC Res Notes. 2015 Aug 4;8:332. doi: 10.1186/s13104-015-1285-7.
8
The roles of CRISPR-Cas systems in adaptive immunity and beyond.
Curr Opin Immunol. 2015 Feb;32:36-41. doi: 10.1016/j.coi.2014.12.008. Epub 2015 Jan 6.
9
Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems.
Science. 2016 Aug 5;353(6299):aad5147. doi: 10.1126/science.aad5147.
10
Viral diversity threshold for adaptive immunity in prokaryotes.
mBio. 2012 Dec 4;3(6):e00456-12. doi: 10.1128/mBio.00456-12.
引用本文的文献
1
Exploring Virulence Characteristics of Clinical Isolates from Greece.
Microorganisms. 2025 Jun 26;13(7):1488. doi: 10.3390/microorganisms13071488.
2
Exploring virulence characteristics of Klebsiella pneumoniae isolates recovered from a Greek hospital.
Mol Genet Genomics. 2025 May 26;300(1):52. doi: 10.1007/s00438-025-02258-2.
3
Advances in CRISPR/Cas-Based Strategies on Zoonosis.
Transbound Emerg Dis. 2023 Aug 3;2023:9098445. doi: 10.1155/2023/9098445. eCollection 2023.
4
Exploring the comparative genome of rice pathogen : unveiling virulence, fitness traits, and a potential type III secretion system effector.
Front Plant Sci. 2024 May 23;15:1416253. doi: 10.3389/fpls.2024.1416253. eCollection 2024.
5
Prevalence of the CRISPR-cas system and its association with antibiotic resistance in clinical Klebsiella pneumoniae isolates.
BMC Infect Dis. 2024 Jun 3;24(1):554. doi: 10.1186/s12879-024-09451-5.
6
Analysis of twelve genomes of the bacterium from brown-throated sloths (), the first from a non-human host.
PeerJ. 2024 Apr 4;12:e17206. doi: 10.7717/peerj.17206. eCollection 2024.
7
Exploring the Interplay of the CRISPR-CAS System with Antibiotic Resistance in : A Poultry Meat Study from Lahore, Pakistan.
Medicina (Kaunas). 2024 Jan 10;60(1):130. doi: 10.3390/medicina60010130.
8
Correlation of CRISPR/Cas and Antimicrobial Resistance in Clinical Isolates Recovered from Patients in Egypt Compared to Global Strains.
Microorganisms. 2023 Jul 30;11(8):1948. doi: 10.3390/microorganisms11081948.
9
Prevalence and analysis of CRISPR/Cas systems in Pseudomonas aeruginosa isolates from Greece.
Mol Genet Genomics. 2022 Nov;297(6):1767-1776. doi: 10.1007/s00438-022-01957-4. Epub 2022 Oct 5.
10
Genomic Insights Into the Interspecific Diversity and Evolution of , a Pathogen Associated With Bacterial Vaginosis.
Front Microbiol. 2022 Jul 5;13:939406. doi: 10.3389/fmicb.2022.939406. eCollection 2022.
本文引用的文献
1
Prevalence, conservation and functional analysis of Yersinia and Escherichia CRISPR regions in clinical Pseudomonas aeruginosa isolates.
Microbiology (Reading). 2011 Feb;157(2):430-437. doi: 10.1099/mic.0.045732-0.
2
Dealing with the evolutionary downside of CRISPR immunity: bacteria and beneficial plasmids.
PLoS Genet. 2013;9(9):e1003844. doi: 10.1371/journal.pgen.1003844. Epub 2013 Sep 26.
3
A ruler protein in a complex for antiviral defense determines the length of small interfering CRISPR RNAs.
J Biol Chem. 2013 Sep 27;288(39):27888-97. doi: 10.1074/jbc.M113.499244. Epub 2013 Aug 9.
4
Genetic basis for in vitro and in vivo resistance to lincosamides, streptogramins A, and pleuromutilins (LSAP phenotype) in Enterococcus faecium.
Antimicrob Agents Chemother. 2013 Sep;57(9):4463-9. doi: 10.1128/AAC.01030-13. Epub 2013 Jul 8.
5
A CRISPR/Cas system mediates bacterial innate immune evasion and virulence.
Nature. 2013 May 9;497(7448):254-7. doi: 10.1038/nature12048. Epub 2013 Apr 14.
6
The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
RNA Biol. 2013 May;10(5):726-37. doi: 10.4161/rna.24321. Epub 2013 Apr 5.
7
The CRISPR-associated gene cas2 of Legionella pneumophila is required for intracellular infection of amoebae.
mBio. 2013 Mar 12;4(2):e00074-13. doi: 10.1128/mBio.00074-13.
8
CRISPR-Cas: evolution of an RNA-based adaptive immunity system in prokaryotes.
RNA Biol. 2013 May;10(5):679-86. doi: 10.4161/rna.24022. Epub 2013 Feb 25.
9
First indication for a functional CRISPR/Cas system in Francisella tularensis.
Int J Med Microbiol. 2013 Mar;303(2):51-60. doi: 10.1016/j.ijmm.2012.11.004. Epub 2013 Jan 18.
10
The CRISPRs, they are a-changin': how prokaryotes generate adaptive immunity.
Annu Rev Genet. 2012;46:311-39. doi: 10.1146/annurev-genet-110711-155447.
Zotero 插件